<DOC>
	<DOCNO>NCT01564875</DOCNO>
	<brief_summary>Study design - Multicenter , double-dummy , double-blinded , randomize , Phase 4 study - Patients randomize either study group control group 1:1 ratio , orally administer assign drug Study Objective -The study design demonstrate efficacy safety morning dose Simvast Controlled Release ( CR ) Tab inferior even dose Zocor Tab patient stage 3,4,5 chronic kidney disease hyperlipidemia Primary objective -to ass percent change LDL-C Week 8 baseline Chronic Kidney Disease ( CKD ) stage 3,4,5 hyperlipidemia subject .</brief_summary>
	<brief_title>Efficacy Safety Simvast Controlled Release ( CR ) Zocor Chronic Kidney Disease ( CKD ) Stage 3 , 4 5 Patients With Hyperlipidemia</brief_title>
	<detailed_description>The secondary objective study follow : - ass change percent change TC , HDL-C , TG baseline . - assess accomplishment rate therapeutic goal base therapeutic guidance hyperlipidemia Korean Society Lipidology Atherosclerosis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Inclusion criterion : Patient age 20 75 ( inclusive ) Patients fast serum lipid panel meet following : At Visit 1 screen 100mg/dL ≤ LDLC &lt; 220 mg/dL Triglyceride &lt; 400mg/dL However , patient treat antihyperlipidemics 4 consecutive week long time screening , 100mg/ dL ≤ LDLC &lt; 160 mg/dL . At Visit 2 screen 100mg/dL ≤ LDLC &lt; 220 mg/dL Triglyceride &lt; 400mg/dL Patients CKD stage 3 5 . Subjects consider require medication principal investigator base therapeutic guidance hyperlipidemia Korean Society Lipidology Atherosclerosis . Patients understand study procedure sign informed consent form . Exclusion criterion : Patients hypersensitivity HMGCoA reductase inhibitor ingredient . Patients consume 14 unit alcohol week , consider history drug overdose within 12 month screen investigator , abuse drug . Patients follow history : Active gallbladder disease within 12 month screen ( patient cholecystectomy eligible study ) . Pancreatitis liver disease ( AST ALT &gt; 2 time upper limit normal range Visits 1 2 ) . Patients uncontrolled diabetes mellitus ( HbA1c ≥ 9.0 % ) . Patients hypotension ( systolic blood pressure &lt; 90mmHg diastolic blood pressure &lt; 50mmHg ) . Patients uncontrolled hypertension : mean systolic blood pressure ( SBP ) &gt; 160mmHg mean diastolic blood pressure ( DBP ) &gt; 100mmHg Visit 2 . Patients myocardial infarction coronary artery bypass angioplasty within 6 month screen . Patients stroke , transient ischemic attack ( TIA ) , deep vein thrombosis ( DVT ) within 6 month screen . Patients treat carotid artery disease , peripheral artery disease , abdominal aortic aneurysm . Patients serious heart disease ( patient NYHA class ( Attachment 4 ) III IV congestive heart failure , unstable angina pectoris , acute myocardial infarction ) . Patients diagnosed malignancy within 5 year active tumor . Patients fibromyalgia , myopathy , rhadomyolysis , sudden muscle pain , patient experience adverse event previous treatment statin . Patients mental illness consider investigator serious enough adversely affect patient ' participation study . Patients uncontrolled primary hypothyroidism . Patients active peptic ulcer disease . Patients gastrointestinal condition may restrict drug absorption , chronic diarrhea , inflammatory colic disease , partial ileal bypass , gastrorrhaphy , gastric banding . Screening CPK level &gt; 3 time upper limit normal range . Patients immunosuppressives kidney transplantation . Patients need immunosuppressive reason . Patients participate another clinical trial within last 4 week screen ( except participate clinical trial include observational study involve intervention medication ) . Pregnant woman , lactate woman , woman childbearing potential use appropriate contraceptive . Patients currently dialysis . Other patient consider ineligible principal investigator investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Simvast CR</keyword>
	<keyword>Zocor</keyword>
</DOC>